Prevention of HIV/AIDS

CytoDyn Announces Acceptance of Leronlimab (PRO 140) Data for Presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) in March 2020

Retrieved on: 
Monday, November 18, 2019
Hepatotoxins, Management of HIV/AIDS, Prevention of HIV/AIDS, Zidovudine, Chemical substances, Medical specialties, Chemical compounds, HIV/AIDS

PRESTIGIO is an Italian registry (http://www.registroprestigio.com) involving 40 clinical centers throughout Italy, coordinated by the IRCCS San Raffaele Hospital (Milan).

Key Points: 
  • PRESTIGIO is an Italian registry (http://www.registroprestigio.com) involving 40 clinical centers throughout Italy, coordinated by the IRCCS San Raffaele Hospital (Milan).
  • This is further support for our belief that leronlimab is positioned to change the treatment paradigm in HIV therapy, Dr. Pourhassan concluded.
  • The U.S. Food and Drug Administration (FDA) has granted a "Fast Track" designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • CytoDyn has completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients.

International HIV Experts Call for Focus on Quality of Life Beyond Viral Suppression

Retrieved on: 
Monday, November 18, 2019
AIDS, Health, Infectious diseases, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Health, HIV, Lentiviruses, Prevention of HIV/AIDS, CD4, Management of HIV/AIDS, Treatment as prevention

Recommendations in the white paper, which have been summarised in AIDS Reviews ,1 focus on a new HIV care framework - Health Goals for Me.

Key Points: 
  • Recommendations in the white paper, which have been summarised in AIDS Reviews ,1 focus on a new HIV care framework - Health Goals for Me.
  • The recommendations were developed to support an holistic and individualised long-term treatment approach that goes beyond viral load and CD4 count, to assess health-related quality of life.
  • However, this brings new challenges relating to long-term health; as increasing numbers of people navigate their lives beyond viral suppression and look towards improved quality of life.
  • This international consensus represents an important first step to improve care beyond viral load and ultimately improve the lives of people living with HIV.

GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure

Retrieved on: 
Wednesday, November 13, 2019
Branches of biology, Biology, Articles, Prevention of HIV/AIDS, HIV/AIDS, HIV vaccine, Hypothetical technology, Vaccines, GeoVax, HIV, Gene therapy, HIV/AIDS research

GeoVax will provide its novel boost component (MVA62B) for use in the studies.

Key Points: 
  • GeoVax will provide its novel boost component (MVA62B) for use in the studies.
  • MVA62B is the boosting component for GeoVaxs preventive HIV vaccine (GOVX-B11) which has successfully completed a Phase 2a clinical trial and is awaiting funding in support of a Phase 2b pivotal trial.
  • We are hopeful that the combination of technologies in these studies will yield a promising regimen to purge the latent HIV reservoirs and achieve a much-needed functional cure for HIV.
  • In addition to the UCSF combinatorial trial, GeoVaxs HIV vaccine is also part of collaborative efforts with American Gene Technologies International, Inc. (AGT) to apply its innovative gene therapy approach toward a functional cure for HIV.

HIV Drugs Market Analysis, Trends, and Forecasts, 2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 6, 2019
AIDS, Pharmaceutical, Health, Hepatotoxins, Management of HIV/AIDS, Prevention of HIV/AIDS

The "HIV Drugs - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HIV Drugs - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The HIV Drugs market worldwide is projected to grow by US$6.3 Billion, driven by a compounded growth of 3.6%
    Multi-Class Combination Drugs, one of the segments analyzed and sized in this study, displays the potential to grow at over 4%.
  • Poised to reach over US$10.4 Billion by the year 2025, Multi-Class Combination Drugs will bring in healthy gains adding significant momentum to global growth.
  • In Japan, Multi-Class Combination Drugs will reach a market size of US$549.9 Million by the close of the analysis period.

Global HIV Drugs Market Report 2019-2025: Market is Projected to Grow $6.3 Billion

Retrieved on: 
Wednesday, November 6, 2019
Hepatotoxins, Management of HIV/AIDS, Prevention of HIV/AIDS

DUBLIN, Nov. 6, 2019 /PRNewswire/ -- The "HIV Drugs - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 6, 2019 /PRNewswire/ -- The "HIV Drugs - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The HIV Drugs market worldwide is projected to grow by US$6.3 Billion, driven by a compounded growth of 3.6%
    Multi-Class Combination Drugs, one of the segments analyzed and sized in this study, displays the potential to grow at over 4%.
  • Poised to reach over US$10.4 Billion by the year 2025, Multi-Class Combination Drugs will bring in healthy gains adding significant momentum to global growth.
  • In Japan, Multi-Class Combination Drugs will reach a market size of US$549.9 Million by the close of the analysis period.

Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP®

Retrieved on: 
Wednesday, November 6, 2019
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Clinical medicine, Health, Hepatotoxins, Prevention of HIV/AIDS, RTT, Pre-exposure prophylaxis, Emtricitabine/tenofovir, Tenofovir alafenamide, Gilead Sciences, Clinical endpoint

Descovy demonstrated non-inferior efficacy to Truvada through 96 weeks and statistically significant differences over Truvada for certain key measurements of bone and renal safety assessed in the study, which were pre-specified secondary endpoints.

Key Points: 
  • Descovy demonstrated non-inferior efficacy to Truvada through 96 weeks and statistically significant differences over Truvada for certain key measurements of bone and renal safety assessed in the study, which were pre-specified secondary endpoints.
  • In the DISCOVER trial, 5,387 study participants were randomized in a 1:1 ratio to receive either Descovy or Truvada once-daily.
  • Among the 2,665 participants who received Truvada for the duration of the study, 15 acquired HIV (incidence rate: 0.30/100 PY).
  • U.S. full Prescribing Information for Descovy and Truvada, including BOXED WARNINGS, is available at www.gilead.com
    Descovy, Descovy for PrEP, Truvada, Truvada for PrEP and Gilead are trademarks of Gilead Sciences, Inc. or its related companies.

GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV

Retrieved on: 
Thursday, October 24, 2019
Health, Prevention of HIV/AIDS, Vaccines, Pharmacology, HIV vaccine, HIV/AIDS, Hypothetical technology, GeoVax, Clinical trial

(OTCQB: GOVX) announced today its participation in a planned clinical trial led by researchers at American Gene Technologies (AGT) ( www.americangene.com ), to develop a therapy aimed at eliminating HIV from infected people.

Key Points: 
  • (OTCQB: GOVX) announced today its participation in a planned clinical trial led by researchers at American Gene Technologies (AGT) ( www.americangene.com ), to develop a therapy aimed at eliminating HIV from infected people.
  • AGT expects to begin recruiting patients for the Phase 1 study in January.
  • MVA62B is the boosting component for GeoVaxs preventive HIV vaccine (GOVX-B11) which has successfully completed a Phase 2a clinical trial and is awaiting funding in support of a Phase 2b pivotal trial.
  • GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so.

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically Suppressed Adults with HIV-1

Retrieved on: 
Wednesday, October 16, 2019
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Hepatotoxins, Drugs, RTT, HIV/AIDS, Medical specialties, Integrase inhibitors, Prevention of HIV/AIDS, Management of HIV/AIDS, Lamivudine, Dolutegravir/lamivudine, Zidovudine, Dolutegravir, ViiV Healthcare, GSK

Todays submission takes us a step closer toward offering this option for virologically suppressed adults living with HIV who are looking to treat HIV with fewer drugs.

Key Points: 
  • Todays submission takes us a step closer toward offering this option for virologically suppressed adults living with HIV who are looking to treat HIV with fewer drugs.
  • Use of Dovato in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure replacing their current therapy is subject to FDA approval.
  • The following ISI is based on the Highlights section of the Prescribing Information for Dovato.
  • 2 Clinical trials.gov Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO).

CAN Community Health and Pueblo Family Physicians Partner to Offer Statewide Mobile HIV Testing and Rapid Start Units

Retrieved on: 
Thursday, October 10, 2019
HIV/AIDS, Retroviridae, Medical specialties, Viruses, Hepatotoxins, Management of HIV/AIDS, Prevention of HIV/AIDS, Diagnosis of HIV/AIDS, HIV, HIV/AIDS in China

(Source: https://www.cdc.gov/hiv/pdf/policies/profiles/cdc-hiv-arizona-SSP.pdf )

Key Points: 
  • (Source: https://www.cdc.gov/hiv/pdf/policies/profiles/cdc-hiv-arizona-SSP.pdf )
    In order to address this growing public health need, CAN Community Health, in partnership with Pueblo Family Physicians, is initiating HIV specialty care programs in Arizona to serve the community.
  • "Pueblo Family Physicians is excited to partner with CAN Community Health to provide a full range of in-house preventive, medical and pharmacy services," said Dr. Douglas Cunningham, Medical Director of Pueblo Family who was recently awarded Top Doctor by Phoenix Magazine.
  • For the last 28 years, CAN Community Health has served the needs of People Living with HIV and other conditions.
  • Pueblo Family Physicians is an informative and engaging medical practice treating the Phoenix and Scottsdale, AZ since 1967 and now alongside CAN Community Health, it will promote the prevention of HIV through free at-home HIV test kits, community outreach, patient care coordination and fast access to HIV medications (Rapid Start).

AHF Calls on Gilead for Major Price Cut on PrEP Drug Descovy Following FDA Approval

Retrieved on: 
Saturday, October 5, 2019
Women, MEN, Pharmaceutical, Gay & Lesbian, Infectious diseases, Consumer, Foundation, Philanthropy, Public policy, Government, FDA, AIDS, Health, Healthcare reform, Prevention of HIV/AIDS, Esters, Medicine, HIV/AIDS, Hepatotoxins, Pre-exposure prophylaxis, AHF, Tenofovir alafenamide, AIDS Healthcare Foundation

As part of its rationale for the pricing request, AHF cited the billions of dollars Gilead has already made on its roster of HIV/AIDS medications.

Key Points: 
  • As part of its rationale for the pricing request, AHF cited the billions of dollars Gilead has already made on its roster of HIV/AIDS medications.
  • Now that it has FDA approval for the wider use of Descovy as PrEP to prevent HIV acquisition, AHF is calling on Gilead to drastically cut the cost of this medication, said Michael Weinstein, president of AHF.
  • Gilead should really do the right thing now and significantly cut the price Descovy.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20191004005523/en/